Comparison · NCT05987709-b7147199
Guardant Shield Blood Test vs Standard of Care: Assess the Percentage of Participants Who Completed Follow-up Testing.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Guardant Shield Blood Test vs Standard of Care: Assess the Percentage of Participants Who Completed Follow-up Testing. Trial comparisons, record NCT05987709-b7147199. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05987709-b7147199
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.307 | 0.693 | wilson | |
| Risk in group 2 | 0.7 | 0.397 | 0.892 | wilson | |
| Risk difference, group 1 minus group 2 | -0.2 | -0.472 | 0.159 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.714 | 0.399 | 1.28 | log | |
| Odds ratio, group 1 over group 2 | 0.429 | 0.0874 | 2.1 | log | |
| Number needed to treat, for one fewer participant with the outcome on Guardant Shield Blood Test than on Standard of Care | 5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Guardant Shield Blood Test | Patients will have the Guardant Shield blood test for colorectal cancer screening.~GuardantSHIELD Blood Test: The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC | 11 | 22 | OG000 |
| Group 2 | Standard of Care | Patients will have standard of care, which is a reminder to do their FIT test for colorectal cancer screening | 7 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Assess the Percentage of Participants Who Completed Follow-up Testing.
- Description
Assess the percentage of participants who completed follow-up colonoscopy within 6 months of their result among individuals with an abnormal non-invasive test result; comparing the blood test and usual care groups.
- Time frame
- Within 6 months of abnormal FIT test
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study of Colorectal Cancer Screening Options
- NCT number
- NCT05987709
- Phases
- NA
- Conditions
- Colon Cancer
- Interventions
- GuardantSHIELD Blood Test
- Lead sponsor
- Kaiser Permanente
- Results first posted
- 2025-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05987709?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05987709-b7147199